Hemoglobinopathies 患者造血干细胞移植后残余供红祖细胞的检测
Summary
对 hemoglobinopathies 患者进行干细胞移植后, 需要对供体细胞进行定量监测植入。流 cytometry-based 细胞分选、菌落形成检测和随后的短串联重复分析的结合可用于评估红室中祖体的增殖和分化。
Abstract
在骨髓移植治疗地中海贫血或镰状细胞疾病的患者中, 有很大比例的病人出现了不完全的嵌。这种观察具有巨大的影响, 因为随后的治疗免疫策略可以改善临床结果。传统上, 聚合酶链 reaction-based 分析短串联重复是用来确定嵌的供体来源的血细胞。然而, 这种方法只限于有核细胞, 不能区分分离的单细胞血统。我们将短串联重复的分析应用于流细胞排列的造血祖细胞, 并将其与从骨中采集的选定的突发形成单元-红菌落所获得的短串联重复的分析进行比较。骨髓.通过这种方法, 我们能够证明红室中供体细胞的不同增殖和分化。这项技术有资格完成目前的监测嵌在干细胞移植的设置, 从而可以应用于未来的临床研究, 干细胞研究和基因治疗的设计试验。
Introduction
异基因造血干细胞移植 (造血) 是唯一可用的治疗方法, 为各种先天遗传性疾病的造血系统, 实现无疾病存活率超过 90%, 否则高度妥协和生命受限患者1。这一重要的治疗工具的功效通过限制前移植方案2的毒性进行了优化, 而且还通过旨在维持稳定的移植功能的干预, 通过密切监测捐助者派生的单元格3,4,5。
一般情况下, 完整的嵌 (CC) 意味着由供体衍生的细胞完全替换 lymphohematopoietic 室, 而混合嵌 (MC) 则用于在各种比例.分裂嵌 (SC) 表示共存的混合嵌观察在单细胞血统, 如在红室。迅速确定嵌的状态后, 造血是至关重要的, 因为它可能有助于确定患者易复发的疾病, 并启动后续免疫策略, 如供体淋巴细胞输注或减少免疫抑制治疗6。
为监测植入后的造血, 开发了几种方法。免疫球蛋白的 Isotyping 和细胞遗传学分析有很差的灵敏度, 并在其检测多态性7,8的能力受到限制。引入荧光原位杂交 (fish) 可以提高造血后嵌监测的灵敏度, 但仅限于性不匹配的同种异体移植9。目前, 聚合酶链反应 (PCR) 是最广泛的方法用于检测嵌, 是基于传统的琼脂糖-丙烯酰胺凝胶电泳的可变数串联重复 (VNTRs) 或短串联重复 (可疑交易)。常规使用定量 PCR 能够在造血后检测到极小部分的残留供体细胞。到目前为止, 研究的主要限制是 MC 检测几乎完全局限于有核细胞的存在, 而不是成熟的红细胞, 即对受 hemoglobinopathies 影响的患者功能至关重要的细胞。在不同血型的患者中, 值得记住的是, cytofluorometric 分析能够利用针对红细胞抗原 ABO 和 c、c、D、e 和 e10的单克隆抗体来鉴别红细胞中的嵌,11. 在红谱系中, 一种不同但非常有趣的评估嵌的方法是红祖细胞的流细胞分选和各种红祖类型的选择, 并在克隆测定中进行培养,接着分析 STR12。这种方法能够量化红室中供者与受体嵌的相对比例, 并可用于维持骨髓移植的策略。
Protocol
Representative Results
Discussion
本研究的目的是为观众提供两种方法的结合, 分析红祖细胞的供者/受体嵌在造血治疗的 hemoglobinopathies 患者中的应用: 1.) 荧光活化电池分选骨髓标本造血祖细胞, 其次为短串联重复和2。骨髓细胞的菌落形成单元, 不同祖类型的菌落分类, 其次是短串联重复的分析。这种方法的新颖之处在于将一项协议中的技术结合在一起, 来评估个别殖民地的捐助者/接受嵌。
这种方法的特殊重?…
Offenlegungen
The authors have nothing to disclose.
Acknowledgements
这项工作得到了 Kinderkrebshilfe Regenbogen 提的支持。
Materials
| Ficoll-Paque | GE Healthcare | GE17-1440-02 | Remove RBC |
| 50 mL conical tubes | Falcon | 14-432-22 | Sample preparation |
| 12 x 75 mm flow tubes | Falcon | 352002 | FACS sorting |
| Phosphate buffered saline | Gibco | 10010023 | PBS |
| Fetal calf serum | Invitrogen Inc. | 16000-044 | FCS (heat-inactivated) |
| CD34 APC | BD Bioscience | 561209 | FACS-Ab |
| CD36 FITC | BD Bioscience | 555454 | FACS-Ab |
| CD45 V450 | BD Bioscience | 642275 | FACS-Ab |
| Trypan blue | Gibco | 15250061 | |
| Hemocytometer | Invitrogen Inc. | C10227 | Automatic cell counting |
| Hank’s Balanced Salt Solution | Gibco | 14025092 | Suspension buffer in FACS analysis |
| HEPES | Gibco | 15630080 | Component of suspension buffer |
| FcR | BD Bioscience | 564220 | Block FCR |
| FACS Aria I | BD Bioscience | 23-11539-00 | FACS Sorter |
| Recombinant human erythropoietin | Affimetrix eBioscience | 14-8992-80 | EPO |
| Isocove’s Modified Dulbecco’s Medium | Gibco | 12440053 | IMDM |
| L-Glutamine | Invitrogen | 25030-081 | Component of Culture Medium |
| CD34+ magnetic beads | Milteny Biotech | 130-046-702 | CD34+ purification |
| Recombinant human G-CSF | Gibco | PHC2031 | CFU-Assay |
| Recombinant human SCF | Gibco | CTP2113 | CFU-Assay |
| Recombinant human GM-CSF | Gibco | PHC2015 | CFU-Assay |
| Recombinant human IL-3 | BD Bioscience | 554604 | CFU-Assay |
| Recombinant human IL-6 | BD Bioscience | 550071 | CFU-Assay |
| Methocult H4434 Medium | Stemcell Technologies | 4444 | CFU-Assay |
| QiAmp DNA Blood extraction kit | Qiagen | 51306 | DNA Isolation |
| Nanodrop ND-1000 spectra photometer | Thermo Scientific | ND 1000 | DNA Quantification |
| DNAase free H2O | Thermo Scientific | FEREN0521 | DNA Preparation |
| AmplTaq Gold DNA Polymerase | Applied Bioscience | N8080240 | PCR |
| Eppendorf mastercycler gradient | Eppendorf | 6321000019 | PCR |
| Hi-Di Formamid | Applied Bioscience | 4311320 | PCR |
| GeneScan 500 ROX Size Standard | Applied Bioscience | 4310361 | PCR |
| 3130 Genetic Analyzer | Applied Bioscience | 313001R | PCR |
Referenzen
- Angelucci, E., et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 99, 811-820 (2014).
- Lucarelli, G., Isgro, A., Sodani, P., Gaziev, J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2, a011825 (2012).
- Andreani, M., Testi, M., Lucarelli, G. Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance. Tissue Antigens. 83, 137-146 (2014).
- Andreani, M., et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 87, 3494-3499 (1996).
- Andreani, M., et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25, 401-404 (2000).
- Kumar, A. J., et al. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 19, 1094-1101 (2013).
- Lawler, S. D., Harris, H., Millar, J., Barrett, A., Powles, R. L. Cytogenetic follow-up studies of recipients of T-cell depleted allogeneic bone marrow. Br J Haematol. 65, 143-150 (1987).
- McCann, S. R., Crampe, M., Molloy, K., Lawler, M. Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci. 32, 55-61 (2005).
- Dewald, G., et al. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. Am J Med Genet. 76, 318-326 (1998).
- Andreani, M., et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica. 96, 128-133 (2011).
- Andreani, M., Testi, M., Battarra, M., Lucarelli, G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism. 2, 21-22 (2011).
- Kropshofer, G., Sopper, S., Steurer, M., Schwinger, W., Crazzolara, R. Successful management of mixed chimerism after bone marrow transplant in beta-thalassemia major. Am J Hematol. 91, E357-E358 (2016).
- Kimpton, C. P., et al. Automated DNA profiling employing multiplex amplification of short tandem repeat loci. PCR Methods Appl. 3, 13-22 (1993).
- Centis, F., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 96, 3624-3629 (2000).
- Miccio, A., et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U.S.A. 105, 10547-10552 (2008).
